Clinical Trial Update: Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II trial evaluating isoquercetin as an adjunct to first-line sunitinib in renal cell carcinoma (kidney cancer).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Isoquercetin (isoquercetin)
• Sutent (sunitinib)

Snippet

Sponsor: Consorzio Oncotech | Conditions: Renal Cell Carcinoma, Kidney Cancer | Phase 1, Phase 2 | Status: UNKNOWN